Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a decrease of 23.5% from the February 13th total of 79,900 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 300 shares, the short-interest ratio is currently 203.7 days.

Genmab A/S Price Performance

OTCMKTS:GNMSF traded down $0.90 during mid-day trading on Tuesday, hitting $204.08. The company's stock had a trading volume of 223 shares, compared to its average volume of 3,048. The business's fifty day moving average is $210.60 and its two-hundred day moving average is $221.88. The stock has a market cap of $13.48 billion, a price-to-earnings ratio of 11.65 and a beta of 1.08. Genmab A/S has a 1 year low of $186.61 and a 1 year high of $310.56.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.